Search clinical trials for: NVA237 50.0 µg once daily

Total 621 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Germany, Hungary, Belgium, Poland, Spain, Netherlands
AstraZeneca
Parexel

Completed

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

Asthma

United States, Germany, South Africa, Ukraine, Japan, Hungary, Poland, Bulgaria
Eli Lilly and Company

Completed

Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma

Glioblastoma Multiforme

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial of OPC-64005 for Major Depressive Disorder

Major Depressive Disorder

Japan
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
AstraZeneca

Completed

A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma

Asthma | Efficacy | Safety

Germany, Bulgaria
Kowa Company, Ltd.

Recruiting

A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Hypercholesterolemia

Japan
Inflazyme Pharmaceuticals Ltd

Completed

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

Asthma

United States
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States
Acologix, Inc.

Unknown

A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) (AC120-8231)

Uremic Pruritus
Dr. Reddy's Laboratories Limited

Completed

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Actinic Keratosis (AK)

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Parkinson Disease

United States, France, Israel, Germany
Spectrum Pharmaceuticals, Inc

Terminated

Study of Poziotinib in Japanese Patients With NSCLC

NSCLC

Japan
Kowa Company, Ltd.

Completed

A Phase III Confirmatory Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
Unity Health Toronto

Completed

Screening Frequency Trial to Identify Weaning Candidates (RELEASE)

Critically Ill

Canada
Novartis Pharmaceuticals

Completed

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Case Western Reserve University
National Institute of Nursing Research (NINR); MetroHealth Medical Center

Completed

Dose of Early Therapeutic Mobility: Does Type or Frequency Matter? (ETM)

Critical Illness

United States
Unity Health Toronto

Completed

Screening Elderly Patients for Weaning

Critically Ill

Canada
Kowa Company, Ltd.

Completed

A Phase III Long Term Study of K-877 Extended Release Tablet

Dyslipidemias

Japan
National Cancer Institute, Egypt

Unknown

Whole Breast Irradiation vs Twice Daily vs. Once Daily Accelerated Partial Breast Irradiation

Breast Cancer | Radiation Toxicity

Egypt
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Mimetica Pty Limited

Completed

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

Acne Vulgaris

United States
Garden of Life, LLC
Validcare, LLC

Active, not recruiting

Garden of Life Once Daily Women's Probiotic: Vaginal pH and Quality of Life Study

Vaginal Health

United States
Maruho Co., Ltd.

Completed

Open-label Study of ASP2151 in Herpes Simplex Patients

Herpes Simplex

Japan
Enterprise Therapeutics Ltd

Completed

A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects

Cystic Fibrosis

United Kingdom
Kowa Company, Ltd.

Active, not recruiting

A Phase III Confirmatory Study of K-237

Covid19

Japan, Thailand
Taro Pharmaceuticals USA

Completed

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

Psoriasis

United States
MerLion Pharmaceuticals GmbH

Completed

Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis

Urinary Tract Infections | Acute Pyelonephritis

Germany
Unity Health Toronto

Unknown

Frequency of Screening and SBT Technique Trial (FAST)

Critically Ill

Canada, United States
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

China
Rhythm Pharmaceuticals, Inc.

Approved for marketing

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)

Obesity | Bardet-Biedl Syndrome (BBS)
Podimetrics, Inc.
Kaiser Permanente Mid-Atlantic States Mid-Atlantic Permanente Medical Group...

Completed

Impact of Remote Foot Temperature Monitoring

Foot Ulcer, Diabetic

United States
Unity Health Toronto

Unknown

The Frequency of Screening and SBT Technique Trial: The FAST Trial

Critically Ill

Canada, United States
Peter Rossing

Completed

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes (DapKid)

Diabetic Nephropathy | Type 2 Diabetes

Denmark
The Christie NHS Foundation Trust
Cancer Research UK; European Organisation for Research and Treatment of Cancer... and other collaborators

Completed

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer (CONVERT)

Lung Cancer

United Kingdom
Centre Antoine Lacassagne

Recruiting

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy (P1V2)

Osteosarcoma | Ewing Sarcoma | Chondrosarcoma | Chordoma

France
LEO Pharma

Completed

Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis

Actinic Keratosis

Australia
Mayo Clinic
National Cancer Institute (NCI)

Completed

Three Different Programs of Paced Breathing in Treating Hot Flashes in Women

Breast Cancer | Fatigue | Hot Flashes | Sleep Disorders

United States
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Anhui Palo Alto Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis

Allergic Rhinitis

China
Novartis Pharmaceuticals

Terminated

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma

Germany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
Biolab Sanus Farmaceutica
Medcin Instituto da Pele

Not yet recruiting

Stryphnodendron Adstringens Intimate Soap

Vaginal Flora Imbalance

Brazil
Radboud University Medical Center
Astellas Pharma Europe B.V.

Completed

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response (ILUMINATE)

Metastatic Castration Resistant Prostate Cancer

Netherlands
LG Life Sciences

Completed

Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of
Laboratorio Elea Phoenix S.A.
Universidad Nacional de Salta; Centro de Investigación Veterinaria Tandil CIVETAN and other collaborators

Completed

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

COVID-19 Drug Treatment

Argentina
National Cancer Center, Korea

Unknown

Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer

Limited Disease Small Cell Lung Cancer

Korea, Republic of
CONRAD
National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaborators

Completed

Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel

HIV Prevention

United States

Search clinical trials for: NVA237 50.0 µg once daily

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations